

# Vaccine Contract Manufacturing Market Size to Reach Revenues of around USD 4 Billion by 2026 – Arizton

The global vaccine contract manufacturing market size to reach USD 4 billion by 2026, growing at a CAGR of 13% during the period 2021-2026.

CHICAGO, ILLINOIS, UNITED STATES, May 3, 2021 /EINPresswire.com/ -- In-depth analysis and data-driven insights on the impact of COVID-19 included in this global <u>vaccine contract</u> <u>manufacturing market</u> report.

The vaccine contract manufacturing market is expected to grow at a CAGR of approximately 13% during the period 2020–2026.

### Key Highlights Offered in the Report:

- 1. The global vaccine contract manufacturing market is expected to grow with an incremental growth of around USD 2 billion and absolute growth of around 104% during the forecast period.
- 2. In scale of operation, the commercial segment has the highest share of around 64% due to high uptake of vaccines as well as growing vaccine pipeline and is likely to witness highest incremental growth of around USD 1.3 billion during the forecast period.
- 3. Subunit vaccines have a major share of around 33% among the other types of vaccines that include live-attenuated, inactivated, RNA vaccines, and others.
- 4. Eill and finish services in the service segment had a high share of around 67% and is expected to witness an incremental growth of around USD 1.4 billion during the forecast period.
- 5. North America accounted for the highest share of around 35% in the vaccine contract manufacturing market with the US accounting for a share of over 90% and Canada with a share of approximately 10%.
- 6. The advent of COVID-19 has increased the need for vaccines and major vaccine developers and manufacturers formed international alliances to fulfill the high demand for vaccines.

# Key Offerings:

- •Market Size & Forecast by Revenue | 2020-2026
- •Market Dynamics Leading trends, growth drivers, restraints, and investment opportunities
- •Market Segmentation A detailed analysis by scale of operation, vaccine type, services, and geography
- Competitive Landscape 14 key vendors and 48 other vendors

## Get your sample today!

Vaccine Contract Manufacturing Market - Segmentation

- •The global commercial vaccine contract manufacturing market accounted for over 64% in 2020. There has been a high demand for contract manufacturing services due to the growth in infectious diseases and the onset of endemics and pandemics worldwide. North America expects to contribute maximum revenue to the commercial vaccine market due to the increased focus to prevent deaths caused by vaccine-preventable diseases.
- •Bub-unit vaccines accounted for a major share of approx. 34% in 2020, and they are likely to witness the highest incremental growth of over USD 633 million during the forecast period. Growing infectious diseases leading to endemic/pandemics, majorly due to decreasing immunization coverage in many regions, have made national and international bodies implement vaccination programs strictly, allowing more people to get vaccinated.
- •The fill/finish services market expects to grow at a CAGR of approx. 13% during 2020-2026. Fill/finish services are subject to extreme scrutiny by regulatory agencies and tend to be costly in the manufacturing process. Hence, vaccine manufacturers outsource these services to CMOs, which help them meet unexpected demands, source policies or better matching scales. Moreover, biopharmaceutical companies outsource fill-and-finish needs to gain access to specialized technology.

Vaccine Contract Manufacturing Market by Scale of Operation

- Commercial
- •**C**linical
- •Bre-clinical

Vaccine Contract Manufacturing Market by Vaccine Type

- •Bub-unit
- □ive Attenuated
- •Inactivated
- •RNA
- Others

Vaccine Contract Manufacturing Market by Services

- ⊞ill/Finish
- Analytical & QC Studies
- □ell/Virus Banking
- Others

Vaccine Contract Manufacturing Market - Dynamics

Vaccination is one of the most powerful and economical tools against potentially lethal infectious diseases. According to the WHO, up to 3 million human lives are saved each year due to vaccination. Though vaccines have been manufactured for several decades, vaccine

development technology has seen recent significant improvements and new vaccine modalities on the rise. In addition, the COVID-19 pandemic has highlighted the need for innovative and faster manufacturing capabilities to address the demand for vaccines. With the advent of epidemics and pandemics in previous years, the manufacturing of vaccines has been the most important task for manufacturers. The race for developing a vaccine is intensifying, and various countries are speeding up their production capacity on a larger scale. Vaccine developers are approaching contract manufacturers to utilize their manufacturing facilities for large-scale production of vaccines in the midst of outbreaks such as COVID-19.

Key Drivers and Trends fueling Market Growth:

- •Global Vaccination Programs for COVID-19
- •Growing Agreements Between Vaccine Developers and Contract Manufacturers
- Eavorable Patient Demographics & Growing Vaccinations of Newborns and Children
- Effect of Epidemics & Pandemics on Vaccine Development

Vaccine Contract Manufacturing Market – Geography

Major factors driving the growth of the North American vaccine contract manufacturing market include growing population, the prevalence of infectious diseases, increasing demand for vaccines, expanding biopharmaceutical industry, growing urbanization and industrialization, increased demand for introduction of vaccines, and rising awareness of vaccines in developing countries. The demand for vaccines has been growing in the North American region due to the prevalence of infectious or vaccine-preventable diseases. These diseases are considerable effects of international travel, global warming, bioterrorism, the presence of vectors, and the growing importation of wildlife. Infectious diseases such as Tuberculosis, Haemophilus influenzae type b (Hib), Hepatitis B, Meningococcal Meningitis, Tetanus, Diphtheria, Measles, Yellow Fever, And Whooping Cough accounted for the most common infectious diseases in North America.

Get your sample today! <a href="https://www.arizton.com/market-reports/vaccine-contract-manufacturing-market">https://www.arizton.com/market-reports/vaccine-contract-manufacturing-market</a>

Vaccine Contract Manufacturing Market by Geography

- •North America
- •**U**S
- •**C**anada
- •Burope
- •**U**K
- •Germany
- •Brance
- •Italy
- •Bpain
- •APAC
- •[[hina

- •India
- •Japan
- •Bouth Korea
- Australia
- •□atin America
- Mexico
- Brazil
- Argentina
- •Middle East & Africa
- •Baudi Arabia
- Turkey
- •Bouth Africa

### **Major Vendors**

- ·Ajinomoto Bio-Pharma
- •Albany Molecular Research (AMRI)
- •**□**atalent
- □ytovance Biologics
- Emergent BioSolutions
- •BUJIFILM
- •GlaxoSmithKline
- •IDT Biologika
- □onza
- •Merck KGaA
- •Bfizer
- •Recipharm
- •Berum Institute of India
- Biegfried Holding

### Other Prominent Vendors

- •**□**obra Biologics
- •Baxter BioPharma Solutions
- •Goodwin Biotechnology
- **KBI** Biopharma
- •Banofi
- BioMARC
- •Bavarian Nordic
- Tharles River Laboratories
- •Boehringer Ingelheim
- Bamsung Biologics
- Meridian Life Science
- Wacker Biotech B.V
- Jubilant Hollister Stier

- AbbVie
- •Novasep
- •Kemwell Biopharma
- •Northway Biotech
- •Midas Pharma
- •Alcami
- 🛚 ambrex
- Asymchem
- •Bharmaceutics International Inc. (Pii)
- •Bharp
- Bingota Solutions
- •Thermo Fisher Scientific
- Kaneka Eurogentec
- •Richter-Helm BioLogics
- Dlogy Bioservices
- Corden Pharma
- •Derbios Pharma
- •BSP Pharmaceuticals
- •JOINN Biologics
- •Burofins Scientific
- •ProBioGen
- •Bsco Aster
- •Genovior Biotech
- AGC Biologics
- •BirGenix
- Amaran Biotech
- •Eden Biologics
- •Abzena
- •Aldevron
- •☐ell Culture Company
- Taron Solutions
- •MabPlex
- •Axcellerate Pharma
- WuXi Biologics
- •IIherapure Biopharma

Looking for more information? Click Here

**Jessica** 

Arizton Advisory and Inteligence

+1 312-235-2040

email us here

Visit us on social media:

# Facebook Twitter LinkedIn

This press release can be viewed online at: https://www.einpresswire.com/article/540113370

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information. © 1995-2021 IPD Group, Inc. All Right Reserved.